Neuralink vs Paradromics
Side-by-side equity comparison for employees weighing offers at Neuralink or Paradromics. Valuations, funding history, headcount growth, and secondary-market context.
| Neuralink | Paradromics | |
|---|---|---|
| Latest valuation | $10B | Not publicly disclosed |
| Latest round | Series D | Series B |
| Round date | November 2024 | — |
| Total raised | $680M | $85M |
| Founded | 2016 | 2015 |
| Headquarters | Fremont, CA | Austin, TX |
| Employees | 628 | 100 |
| Employee YoY growth | +19% | +18% |
| Primary industry | Healthcare & Biotech | Healthcare & Biotech |
| Secondary-market price | — | — |
| Base-case equity multiple | 1x | 2x |
| Upside equity multiple | 1x | 4x |
| Lead investors | Founders Fund, GV (Google Ventures) | — |
| Status | private | private |
Overview
Neuralink develops implantable brain-computer interfaces designed to enable people with paralysis to control digital devices with their thoughts.
Paradromics develops high-bandwidth brain-computer interfaces with thousands of electrodes for restoring speech and motor function to people with paralysis.
Why we compare these
Neuralink appears on Sara's List 2024; Paradromics is a direct competitor we track alongside it.
If you're evaluating offers at either one, the equity math depends on more than the headline valuation — dilution, strike price, time to liquidity, and concentration risk all matter. Use our equity compensation calculator and exit calculator to model your own numbers.